24/7 Market News Snapshot 14 January, 2025 – Nexalin Technology, Inc. Common Stock (NASDAQ:NXL)

January 14, 2025

DENVER, Colo., 14 January, 2025 (247marketnews.com) – (NASDAQ:NXL) are discussed in this article.
Nexalin Technology, Inc. (NXL) has garnered significant attention within the financial sector as it continues to advance its groundbreaking Deep Intracranial Frequency Stimulation (DIFS) technology aimed at revolutionizing mental health treatments. Today, the stock opened at $3.00 but is currently trading at $2.83, reflecting a notable decline of 12.75% from the previous session, which closed at $2.51. With trading volume reaching 651.12K, investor interest remains elevated, despite the recent downturn. Key support may be identified around the previous close price, while resistance could emerge near $3.00, indicating an overall bearish trend that necessitates caution for potential investors.

On the clinical front, Nexalin’s DIFS technology has shown a remarkable 65% response rate in treating major depressive disorder during recent trials, significantly outperforming conventional antidepressants. Research findings also indicate promising results for Alzheimer’s treatment, showcasing increased neuronal activity and blood flow in essential brain regions, which may pave the way for new therapeutic avenues.

Moreover, Nexalin is placing a strategic emphasis on veterans’ mental health by actively collaborating with esteemed institutions to tackle conditions like traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD). The establishment of Nexalin America, a subsidiary focused on serving military personnel and veterans, underscores this commitment.

The company’s introduction of a virtual clinic, integrated with AI features, represents a pivotal shift in delivering mental health care, enhancing patient support through real-time data capture and telemedicine capabilities.

With aspirations for expansion into the European market by 2025 via CE Mark approval and ongoing research into insomnia, addiction, and military mental health, Nexalin is well-positioned to seize a significant share of the projected $11 billion global neuromodulation market by 2028, offering innovative and non-invasive solutions in mental health care.

Related news for (NXL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.